Inventor · disambiguated record
Giovanni Coppola
Also filed as: COPPOLA GIOVANNI
9 granted patents·21 pending applications·2 citations·filing 2015–2025
77Inventor score
Top patents by PatentIndex Score
30 records- 0184US11820982B2Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitorsREGENERON PHARMA·Filed 2021·Granted Nov 21, 2023·1 cites·7 claims
- 0284US11674177B2Kelch domain containing 7B (KLHDC7B) variants and uses thereofREGENERON PHARMA·Filed 2021·Granted Jun 13, 2023·1 cites·10 claims
- 0381US12258627B2Kelch domain containing 7B (KLHDC7B) variants and uses thereofREGENERON PHARMA·Filed 2023·Granted Mar 25, 2025·0 cites·19 claims
- 0474US2024148774A1Treatment Of Inflammation With Glucocorticoids And Angiopoietin-Like 7 (ANGPTL7) InhibitorsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0573US2024102013A1Treatment Of Ophthalmic Conditions With Son of Sevenless 2 (SOS2) InhibitorsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0672US2025250631A1Kelch Domain Containing 7B (KLHDC7B) Variants And Uses ThereofREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 0770US11865134B2Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitorsREGENERON PHARMA·Filed 2022·Granted Jan 9, 2024·0 cites·3 claims
- 0868US2025115918A1Treatment Of Uveitis With Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0967US2025129371A1Treatment Of Macular Degeneration With Complement Factor D (CFD) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1065US12370257B2Materials and methods of treating MHC-I-opathy risk haplotypesREGENERON PHARMA·Filed 2022·Granted Jul 29, 2025·0 cites·13 claims
- 1163US11512309B2Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitorsREGENERON PHARMA·Filed 2021·Granted Nov 29, 2022·0 cites·13 claims
- 1263US2023279400A1Methods Of Treating Headaches And Migraines With Sodium Voltage-Gated Channel Alpha Subunit 11 (SCN11A) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1363US2022064735A1Synaptojanin 2 (SYNJ2) Variants And Uses ThereofREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 1462US12157891B2Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitorsREGENERON PHARMA·Filed 2022·Granted Dec 3, 2024·0 cites·9 claims
- 1562US11767526B2Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitorsREGENERON PHARMA·Filed 2020·Granted Sep 26, 2023·0 cites·11 claims
- 1662US2024189456A1Treatment Of Prion DiseasesREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1762US2025375519A1Materials And Methods Of Treating MHC-1-Opathy Risk HaplotypesREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1861US2024247267A1Treatment Of Stroke With 1,4-Alpha-Glucan-Branching Enzyme (GBE1) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1959US2023108957A1Treatment Of Psychiatric Disorders And Psychiatric Disorder-Associated MRI Phenotypes With Stabilin 1 (STAB1) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2059US2024238384A1Treatment Of B27-Negative Uveitis With Inositol Polyphosphate Multikinase (IPMK) Therapeutic Agents Or Indoleamine 2,3-dioxygenase 2 (IDO2) AgonistsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2158US2025136996A1Treatment of smoking with cholinergic receptor nicotinic beta 3 subunit (chrnb3) inhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2257US2020370119A1Synaptojanin 2 (SYNJ2) Variants And Uses ThereofREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 2357US2023034093A1Treatment Of Cognitive Impairment With Alpha-N-Acetylgalactosaminide Alpha-2,6-Sialyltransferase 5 (ST6GALNAC5) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2456US11845989B2Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitorsREGENERON PHARMA·Filed 2020·Granted Dec 19, 2023·0 cites·4 claims
- 2554US2023287422A1Triggering Receptor Expressed On Myeloid Cells 2 (TREM2) Variants And Uses ThereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2653US2021300976A1Fascin-2 (FSCN2) Variants And Uses ThereofREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 2751US2021371930A1Solute Carrier Family 26 Member 5 (SLC26A5) Variants And Uses ThereofREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 2850US2022089664A1Treatment Of Ophthalmic Conditions With Angiopoietin-Like 7 (ANGPTL7) InhibitorsREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 2947US2023059929A1Modulation Of Endoplasmic Reticulum Aminopeptidase 2 (ERAP2)-Mediated Immune ResponseREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 3030US2015190377A1Neuronal regenerationUNIV CALIFORNIA CORP·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Giovanni Coppola files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →